Empowering Axial Spondyloarthritis Awareness: UCB’s Commitment
Introduction: On World AS Day 2024, UCB proudly reaffirms its dedication to supporting individuals grappling with axial spondyloarthritis (axSpA). This year, our focus revolves around the crucial theme of “Signs and Symptoms,” emphasizing the urgency of early detection and diagnosis. Through robust collaborations, we aim to positively impact the lives of those affected by this chronic inflammatory disease.
Partnerships and Awareness: In alliance with esteemed organizations such as the Axial Spondyloarthritis International Federation (ASIF), we tirelessly advocate for axSpA awareness. By educating and engaging patients and bolstering rheumatologists through tailored medical education initiatives, we strive to combat the staggering average diagnostic delay of seven years post-symptom onset.
Recognizing Symptoms: axSpA manifests through debilitating symptoms like back pain, fatigue, and stiffness, often exacerbated after inactivity. Associated conditions such as uveitis, psoriasis, and inflammatory bowel disease further compound the challenges faced by patients. By empowering individuals to recognize and initiate dialogue with healthcare providers about these symptoms, we aim to expedite diagnoses and mitigate irreversible structural damage.
Research and Collaboration: Through rigorous research, strategic partnerships, and targeted medical education, UCB endeavors to minimize the diagnostic gap for axSpA on a global scale. Guided by insights from ASIF’s “Delay to Diagnosis” report, we collaborate with entities like the UK’s National Axial Spondyloarthritis Society (NASS) to streamline public outreach and enhance clinician training programs, with the ultimate goal of achieving a ‘Gold Standard’ one-year time to diagnosis by 2025.
Digital Healthcare Initiatives: UCB addresses critical gaps in the rheumatology patient journey by harnessing the power of digital health platforms. Initiatives like FASTRAX leverage innovative technologies to educate healthcare providers, aiming to improve recognition of inflammatory pain, prevent misassessment, and enhance access to specialized care.
Rheumacensus Program: Our Europe-wide Rheumacensus program spearheads advancements in axSpA care by identifying and addressing unmet patient needs. Through collaboration with stakeholders and comprehensive data analysis, we advocate for tangible improvements in rheumatology clinics, as evidenced by recent findings published in Rheumatology and Therapy.
Medical Education Resources: For healthcare professionals (HCPs), we curate an array of medical education resources in collaboration with clinical experts. Platforms like RheuMuseum and the UCB Med Hub equip HCPs with invaluable insights into axSpA clinical manifestations and the latest immunology advancements, facilitating informed decision-making in their daily practice.
Conclusion: On World AS Day and beyond, UCB remains steadfast in its mission to serve the axSpA community through groundbreaking research, heightened disease awareness, and amplification of patient voices. Together, let us continue to shine a spotlight on the signs and symptoms of axial spondyloarthritis, driving positive change for those impacted by this challenging condition.
